Zobrazeno 1 - 10 of 15 pro vyhledávání: '"Solomon Lubinga"'
1
Akademický článek
Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset
Autor: David Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman, Sumati Rao, Solomon Lubinga, David Stenehjem
Publikováno v: Data in Brief, Vol 37, Iss , Pp 107195- (2021)
While results from clinical trials are important in determining the efficacy of treatment, restrictive eligibility criteria may limit generalizability to patient populations in the real-world setting. Real-world analyses can therefore identify subgro
Externí odkaz: https://doaj.org/article/a764dbdf6af741ba9f3f84cc2b459a8f
Zobrazit plný text záznamu
4
Cost-effectiveness of nivolumab in patients with NSCLC in the United States
Autor: Caitlin Smare, Mohammad A Chaudhary, N. Hertel, Solomon Lubinga, John R. Penrod
Publikováno v: The American Journal of Managed Care. 27:e254-e260
Objectives To determine the lifetime cost-effectiveness of nivolumab vs docetaxel in advanced squamous and nonsquamous non-small cell lung cancer (NSCLC) following platinum-based chemotherapy from a US payer perspective. Study design Trial- and cohor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ed1bf653d1d2513ddb74622731f9a4c
https://doi.org/10.37765/ajmc.2021.88726
Zobrazit plný text záznamu
5
Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer
Autor: Jenny Lam, David M. Waterhouse, Sophie Gao, David D. Stenehjem, Lei Yin, Keith A. Betts, Solomon Lubinga, Yong Yuan, John Hartman, Sumati Rao
Publikováno v: Lung Cancer. 156:41-49
Background First-line (1L) immunotherapy (I-O) has improved outcomes in patients with advanced non-small cell lung cancer (NSCLC) in clinical trials and is now routinely used alone or combined with chemotherapy. Although efficacy and safety of I-O th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9cc473243c3122af6d8aff5188a87a3
https://doi.org/10.1016/j.lungcan.2021.04.007
Zobrazit plný text záznamu
6
Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy
Autor: David D. Stenehjem, Yong Yuan, Wenxi Tang, Sumati Rao, Solomon Lubinga, John Hartman, Keith A. Betts, Mads Jenkins, David M. Waterhouse, Jenny Lam
Publikováno v: Future oncology (London, England). 17(22)
Background: Chemotherapy (CT) alone was previously standard first-line (1L) therapy for metastatic non-small-cell lung cancer (NSCLC) but alternative treatments, including immunotherapy (I-O), are now available. Patients & methods: In this retrospect
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e228157e2afe9c4be17f6ae74c51278a
https://pubmed.ncbi.nlm.nih.gov/33849296
Zobrazit plný text záznamu
7
731 Costs of care for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): a real-world claims analysis
Autor: Dhruv Chopra, Bruce Feinberg, Jonathan Kish, John Hartman, Solomon Lubinga, Djibril Liassou
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Recent advances in therapy have created numerous options for the 1L treatment of aNSCLC. This study describes the total direct healthcare costs for patients treated with immunotherapy monotherapy (IO), chemotherapy (CT), or immunotherapy p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9d1ce3b1252b2f501105283a3f8eb2a
https://doi.org/10.1136/jitc-2020-sitc2020.0731
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje